Immutep (ASX:IMM), (NASDAQ:IMMP) is an Australian biotechnology company at the forefront of developing novel immunotherapy treatments for cancer and autoimmune diseases. Its pivotal project revolves around leveraging LAG-3 (Lymphocyte Activation Gene-3) to harness and amplify the body's immune response to fight disease. Immutep's portfolio includes a range of proprietary product candidates like eftilagimod alpha, a first-in-class antigen-presenting cell (APC) activator currently undergoing numerous clinical trials across various cancer indications. Their mission is to achieve breakthroughs in treatment paradigms and offer new hope to patients suffering from severe medical conditions. Collaborating globally with pharmaceutical companies, Immutep aims to accelerate the development of its therapeutic assets, solidifying its commitment to innovation in healthcare.